Tuberculosis Testing

Global Tuberculosis Testing Market to Reach US$2.9 Billion by 2030

The global market for Tuberculosis Testing estimated at US$2.2 Billion in the year 2024, is expected to reach US$2.9 Billion by 2030, growing at a CAGR of 4.9% over the analysis period 2024-2030. Hospitals, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$1.4 Billion by the end of the analysis period. Growth in the Physicians Office segment is estimated at 4.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$138.6 Million While China is Forecast to Grow at 5.6% CAGR

The Tuberculosis Testing market in the U.S. is estimated at US$138.6 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$383.4 Million by the year 2030 trailing a CAGR of 5.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.7% and 2.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR.

Global Tuberculosis Testing Market - Key Trends & Drivers Summarized

Tuberculosis (TB) remains a major global health challenge, and accurate, timely testing is crucial for effective diagnosis and treatment. Tuberculosis testing involves various methods, including skin tests, blood tests, sputum tests, and molecular diagnostics. The traditional Mantoux tuberculin skin test has been widely used, but newer, more accurate tests like the interferon-gamma release assays (IGRAs) and nucleic acid amplification tests (NAATs) have been developed to improve diagnostic accuracy. These advanced tests provide quicker results and are less affected by prior BCG vaccination, which can cause false positives in skin tests.

The importance of tuberculosis testing is underscored by the high morbidity and mortality rates associated with the disease, particularly in developing countries. Early and accurate detection is critical to controlling the spread of TB and initiating appropriate treatment. Innovations in molecular diagnostics have significantly enhanced the ability to detect TB, including drug-resistant strains, enabling more targeted and effective treatment regimens. Point-of-care testing devices are also becoming more prevalent, allowing for faster diagnosis and treatment initiation in remote and resource-limited settings.

The growth in the tuberculosis testing market is driven by several factors. The increasing prevalence of TB, particularly in high-burden countries, has heightened the need for effective diagnostic solutions. Technological advancements in molecular diagnostics, such as the development of rapid, automated testing platforms, have improved the speed and accuracy of TB detection. The growing incidence of multidrug-resistant TB (MDR-TB) has also spurred the demand for advanced diagnostic tests that can identify resistance patterns and guide appropriate treatment. Additionally, global health initiatives and funding from organizations such as the WHO and the Global Fund to Fight AIDS, Tuberculosis, and Malaria are supporting the development and deployment of TB testing technologies. The integration of TB testing with broader public health efforts, such as HIV screening, further drives the market by enhancing the reach and impact of diagnostic programs.

SCOPE OF STUDY:

The report analyzes the Tuberculosis Testing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Test Type (Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests, Other Test Types); End-Use (Hospitals, Physicians Office, Reference Laboratories, Other End-Uses)

Geographic Regions/Countries:
World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Spain; Russia; Rest of Europe; Asia-Pacific; Australia; India; South Korea; Rest of Asia-Pacific; Latin America; Argentina; Brazil; Mexico; Rest of Latin America; Middle East; Iran; Israel; Saudi Arabia; UAE; Rest of Middle East; Africa.

Select Competitors (Total 55 Featured) -

• Akonni Biosystems, Inc.
• bioMerieux SA
• Creative Diagnostics
• CTK Biotech, Inc.
• DiaSorin SpA
• Jiangsu Medomics Medical Technology Co., Ltd.
• NeoGenomics Laboratories, Inc.
• QIAGEN GmbH
• Siemens Healthineers AG
• Takara Bio, Inc.
• Thermo Fisher Scientific, Inc.
• ZeptoMetrix LLC

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.